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Available online 3 October 2018Background: Adapted ketogenic diet (AKD) and caloric restriction (CR) have been suggested as alternative ther-
apeutic strategies for inflammatory, hyperproliferative and neurodegenerative diseases. Pro-inflammatory eicos-
anoids have been implicated in the pathogenesis of multiple sclerosis since they augment vascular permeability
and induce leukocyte migration into the brain. We explored the impact of ketogenic diets on gene expression of
biosynthetic enzymes for pro- (ALOX5, COX1, COX2) and anti-inflammatory (ALOX15) eicosanoids in patients
with relapsing-remitting multiple sclerosis.
Methods: 60 adultswere prospectively recruited for this sixmonths randomized controlled trial and the impact of
dietary treatment on the Multiple Sclerosis Quality of Life-54 index (ClinicalTrials.gov (NCT01538355) has pre-
viously been published. Herewe explored 24 patients (8 controls, 5 on CR and 11 onAKD). For statistical analysis
we combined the two diet groups to a single pooled treatment group.
Findings: Inter-group comparison indicated that expression of the pro-inflammatory ALOX5 in the pooled treat-
ment group was significantly (p b 0.05) reduced when compared with the control group. Moreover, intra-group
comparison (same individuals before and after dietary treatment) suggested significantly impaired expression of
other pro-inflammatory enzymes, such as COX1 (p b 0.001) and COX2 (p b 0.05). Finally, pretreatment cross-
group analysis revealed a significant positive correlation between expression of pro-inflammatory ALOX5 and
COX2 and an inverse correlation of ALOX5 and COX1 expression with the MSQoL-54 index.
Interpretation: Ketogenic diets can reduce the expression of enzymes involved in the biosynthesis of pro-
inflammatory eicosanoids. Pharmacological interference with eicosanoid biosynthesis might constitute a strate-
gy supplementing current therapeutic approaches for MS., Univers














Multiple sclerosis is a chronic inflammatory demyelinating disease
of the central nervous system (CNS), which is characterized by recur-
rent and progressive demyelination/remyelination cycles. Owing to
the damage of white and gray matter, to axonal destruction and
neuro-inflammation this disease leads to disability in young adults
and finally to a loss of neuronal functionality [1–3]. Demyelination is ac-
companied by depletion of oligodendrocyte precursor cells, by loss of
mature oligodendrocytes, astrogliosis, and infiltration of macrophages,
microglia and T-lymphocytes [4]. Four patterns of morphological de-
struction have been described for multiple sclerosis lesions [5]. Pattern
I and II lesions structurally resemble T-cell-mediated or T-cell plusity Medicine Berlin –
an open access article underantibody-mediated autoimmune encephalomyelitis, respectively. In
contrast, pattern III and IV lesions are characterized by primary oligo-
dendrocyte damage and degeneration, reminiscent of virus- or toxin-
induced demyelination [6].
Fatty acids have been implicated in the pathogenesis of MS and the
omega-3 fatty acid alpha-linolenic acid constitutes an inverse risk factor
[7]. Whether linoleic acid, arachidonic acid (omega-6 fatty acid) and
their metabolites also exhibit protective effects has controversially
been discussed in the literature [8,9]. In the experimental autoimmune
encephalomyelitis model (EAE) [8,10–12], which has frequently been
employed as animal model for human MS, functional inactivation of
the fatty acid metabolizing enzymes ALOX5 and ALOX15 leads to exac-
erbation of the clinical symptoms [13,14]. These data suggest that both
enzymes exhibit protective activities. On the other hand, in human MS
the arachidonic acid cascade appears to be activated during demyelin-
ation and increased expression of ALOX5 and cyclooxygenase-2
(COX2) in lesional areas has been reported [15–18]. Moreover,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
What is already known on this topic
Ketonebodies constitute a vital source of energy during fasting
and low carbohydrate alimentation. They mediate neuroprotec-
tion in neurodegenerative diseases, stroke and traumatic brain in-
jury. Oxidation of ketone bodies is compensated by an equal
reduction in glucose oxidation. COX1, COX2 and ALOX5 are
major pro-inflammatory enzymes, which have been implicated
in demyelination and inflammation in multiple sclerosis and
other chronic inflammatory diseases.
What this study adds
Ketogenic diets and caloric restriction inhibit systemic expres-
sion of key enzymes (COX1, COX2, ALOX5) involved in thebiosyn-
thesis of pro-inflammatory eicosanoids and multiple sclerosis
patients benefit from such dietary treatment.
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prostaglandins have been detected in the cerebro-spinal fluid of multi-
ple sclerosis patients [19–24]. These data suggest a potential role for ei-
cosanoid formation in the pathogenesis of MS and other cerebral
inflammatory diseases. The molecular basis for the pro-inflammatory
role of eicosanoids in these diseases is rather complex but disruption
of the blood brain barrier, which leads to more severe infiltration of pe-
ripheral immune cells into the CNS, clearly contributes [25–27]. In
humanMS the ALOX5 pathway has been implicated inmicroglia activa-
tion and neuro-inflammation and thus, this enzyme also contributes to
axonal damage andmotor neuron dysfunction [20,22]. In early stages of
multiple sclerosis inflammatory blood cells gain access into the brain
taking advantage of the disruption of the blood–brain barrier [28].
These cells release pro-inflammatory mediators including prostaglan-
dins and leukotrienes [29,30] and these lipid mediators impair inter-
neuronal signal transduction, activate cerebral immune cells (microg-
lia) and reduce the blood-brain barrier function of the vascular endothe-
lium even further. Invading neutrophils and monocytes express key
enzymes of eicosanoid biosynthesis (ALOX5, COX1, COX2), which
leads to augmented formation of pro-inflammatory prostaglandins
and leukotrienes in the brain [21,22,26].
In contrast to ALOX5, which constitutes a key enzyme in the biosyn-
thesis of pro-inflammatory leukotrienes, ALOX15 exhibits anti-
inflammatory properties [31,32]. In peripheral leukocytes this enzyme
is mainly expressed in granulocytes (eosinophils, neutrophils) and has
been implicated in the biosynthesis of anti-inflammatory and pro-
resolving mediators such as lipoxins, resolvins and protectins [33–35].
In fact, experimentswith ALOX15 knockoutmice indicated that the clin-
ical symptoms of EAE were significantly worsened when compared
with corresponding control animals [13]. However, these findings
were contradicted by pharmacological intervention studies, in which
baicalein, an ALOX15 inhibitor with potent anti-oxidative properties,
significantly attenuated the clinical severity of EAE [36]. The compound
inhibited migration of autoimmune T cells into the central nervous sys-
tem, reduced activation of microglia, decreased production of pro-
inflammatory cytokines and induced expression of the peroxisome
proliferator-activated receptor (PPAR)β/δ in microglia [36]. Although
inhibition of the ALOX15 pathway has not directly been shown in this
study the findings suggest an important regulatory role of ALOX15 in
CNS inflammation.
For N100 years caloric restriction (CR) and ketogenic diet (KD),
which both induce a metabolic switch from glucose to ketone bodies
(fatty acid breakdown products) as primary brain energy source, are
known for their beneficial effects on pharmaco-resistant seizures inchildren and on disorders of the energy metabolism of the brain
[37–39]. In addition, corresponding human and mouse dietary studies
point towards anti-inflammatory and anti-neurodegenerative effects
of such diets as suggested byMRI studies and histology [40–43]. The ob-
served diet-induced improvement of neuronal resistance and axonal
survival are clearly neuro-protective but the underlying mechanisms
remain elusive [44]. To contribute to this discussion we recently initiat-
ed a randomized clinical trial (NCT01538355), inwhichwe explored the
impact of adapted ketogenic diet (AKD) and CR on quality of life param-
eters in MS patients. In 2014 the study was finalised and improvement
of the health related quality of life index (MSQoL-54) and a decreased
Expanded Disability Status Scale (EDSS) was reported [45]. We also ob-
served a positive impact of AKD on blood lipids and on the intestinal
microbiome [46,47].
In the present study we explored whether AKD and CR may impact
the gene expression patterns of key enzymes of eicosanoid biosynthesis
(ALOX5, COX1, COX2, ALOX15) in peripheral leukocyte.We found a sig-
nificant diet-induced impairment in expression of COX1, COX2 and
ALOX5, which are involved in the biosynthesis of pro-inflammatory
eicosanoids.
2. Materials and methods
2.1. Clinical trial design
This studywas a three-armed parallel grouped, single centered, con-
trolled and randomized clinical pilot trial. The permuted-block random-
ization was generated online at http://randomization.com. An
investigator blind to the randomization plan determined the patients'
randomization number before they underwent randomization. This
study was registered at http://www/clicaltrials.gov as NCT01538355.
2.2. Patients
Patients were randomly allocated to three different experimental
groups: i) AKD for 6 months or ii) CR for 7 days followed by common
carbohydrate intake diet for 6 months or iii) CD (control diet) for
6 months. Before starting the dietary treatment blood was drawn
from all participants for intra-group control purpose. The time interval
of the initial blood removal did not exceed 2 months prior starting the
dietary intervention and after initial blood removal the patients stayed
on their regular diet. After the start of the dietary intervention blood
was drawn again within the first month after changing the diet. At
day 8 blood was taken from CR group patients and from the AKD
and the CD patients blood was drawn between day 9 and day 17
from the start of the dietary intervention. Unfortunately, because of
patients' dropouts and a loss of blood samples during the workup pro-
cedure expression profiles for only 24 patients (8 controls, 5 on CR
and 11 on AKD) could be established (Scheme 1). The patients recruit-
ed originally met the following criteria: Age ≥ 18 ≤ 67 years, stable
disease modifying therapy (DMT) for at least six months prior to in-
clusion, no DMT for at least six months or naive to therapy, expanded
disability status scale (EDSS) ≤ 6.5 and BMI N 18 b 45. Exclusion
criteria were primary or secondary progressive forms of multiple scle-
rosis, clinically relevant heart, lung, liver, and kidney diseases, preg-
nancy or breast-feeding, other neurologic disorders, cancer, weight
loss therapy in the month prior to screening, relapse or steroid pulse
therapy b30 days prior to screening, diabetes or other metabolic de-
fects, bulimia, anorexia and drug abuse.
2.3. Study settings
A local ethics committee approved the study and all participants
gave informed written consent according to the 1964 Declaration of
Helsinki. Relapsing remitting multiple sclerosis patients fulfilling the
Scheme 1. Flow chart of study design.
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Germany and their health status was assessed at the ECRC [48].
2.4. Interventions
Multiple sclerosis patients who met the inclusion criteria (n = 60)
were randomly assigned to three study dietary interventions (n = 20
per groups. To evaluate the food intake we used a 115 item dietary
self-record with additional gaps for unlisted and individual foods or liq-
uids and quantities prospectively over a period of 7 days before baselineand between all other visits (Optidiet software Version 5.1 GOE mbH,
Büro Linden, Linden, Germany).
2.5. Caloric restriction diet (CR)
Single cycle of CR consist of Day 1 – pre-fasting followed by Day 2–8
– very low calorie diet. Day 1-prefasting consists of a 800 kcal (about
40% of normal caloric intake) monodiet (fruit, rice, or potatoes) by pref-
erence of individuals. CR consisted of 100ml vegetable broth or vegeta-
ble juice with 1 tablespoon of linseed oil 3 times daily, plus additional
296 M. Bock et al. / EBioMedicine 36 (2018) 293–303calorie-free liquids. The daily calorie intake was predefined with
200–350 kcal (10–18% of normal caloric intake). We advised patients
to drink 2–3 of unsweetened fluids each day (water, and herbal teas).
After the 7-day fasting period solid foods were stepwise reintroduced
after assessment on day eight.2.6. Adapted ketogenic diet (AKD)
Patients received AKD for 6 months from study outset. The
established therapeutic models of ketogenic diet in children were
adapted by Dr. Bock in regard to increase feasibility of traditional, mod-
ified and Atkins ketogenic diet in adult patients. Thus AKDwas adapted
to achieve i) a modest ketosis (≥500 μmol/l ß-hydroxybutyrate) in
blood, self-measure after dinner twice a week (FreeStyle Precision, Ab-
bott Diabetes Care Ltd.), ii) a modest ketosis (≥500 μmol/l acetoacetate)
in urine, self- measure after dinner once a week (Ketostix, Bayer Con-
sumer Care AG) and iii) to maintain patient compliance. Patients re-
ceived a booklet (Dr. Bock protocol) with meal suggestions over 28
balanced days and were encouraged not to limit fat and vegetables in-
gestion.We adapted the common ketogenic diets to an average daily in-
take of b50 g carbohydrates, N160 g fat (not exceeding omega 6 vs
omega 3 ratio 2:1), average protein intake ≤100 g per day, highfibers in-
take. Patients received detailed information about nutritional facts, gly-
cemic load and learned how to handle carbohydrates by an experienced
nutritional coach.2.7. Control diet (CD)
Patients on CD met the criteria of a regular diet in German popula-
tion as described in the “National Nutrition Survey II” (https://www.
mri.bund.de/de/institute/ernaehrungsverhalten/publikationen/
forschungsprojekte/nvsii/). We advised patients to stay on their regular
diet.2.8. Primary clinical outcome measures
To judge the clinical outcome of this study we quantified the Multi-
ple Sclerosis Quality of Life-54 questionnaire (MSQOL-54), which con-
sists of 54 items. Two composite scores quantifying physical and
mental health were calculated from the outcome of quantification of
the following 12 independent scoring parameters: Physical Function,
Health Perception, Energy/Fatigue, Role Limitations Physical, Pain, Sex-
ual Function, Social Function, Health Distress, Overall Quality of Life,
Emotional Well Being, Role Limitations Emotional, Cognitive Function.
All patients including the control individuals completed the question-
naire before the beginning of dietary treatment as well as 3 and
6 months after the first blood removal. In addition, all members of the
CR group were assessed before breaking the fasting at day 8. The diet-
induced alterations in theMSQOL-54 index,which constitute theprima-
ry outcome measure of this study, have been reported before [45]. This
paper only involves secondary outcome measures and these data have
recently been generated and were not available when the original re-
port was filed [45].2.9. Secondary outcome measures
As secondary outcome measure the expression levels of selected
biosynthetic enzymes of eicosanoid biosynthesis (ALOX5, ALOX15,
COC1, COX2) in peripheral leukocytes were quantified. For this purpose
RNA was extracted from peripheral blood. From the 48 patients who
finished the study the target genes could only be determined for 24
since the blood samples of the remaining patients got lost during the
workup procedure and direct pairing was not possible.2.10. Gene expression analyses
We collected whole blood from all patients in PAXgene blood RNA
tubes. The samples were stored at−80°. RNA isolation was performed
using PAX gene RNA extraction kit. The extracted total RNAwas quanti-
fied (absorbance at 260 nm) and a aliquot was then reversely tran-
scribed into cDNA. The target cDNAs were subsequently quantified by
qRT-PCR employing internal (GAPDH) and external (amplicons for the
genes of interest and the internal standard) amplification standards.
For this purpose the amplicons were prepared by RT-PCR, subcloned
into a suitable cloning vector and amplified to obtain external standard
stock solutions. The real-time PCRs were carried out on a DNA Engine
Opticon® 2 (MJ Research, Inc, Biozym), using the QuantiTect SYBR
Green PCR Kit from Qiagen, according to the recommendations of the
vendors. For amplification of the target genes the primer combinations
specified in Supplemental Table S1 were used and the following PCR
protocol was applied: 15-min hot start at 95 °C, followed by 40 cycles
of denaturation (30 s at 94 °C), annealing (30 s at 60 °C) and synthesis
(30 s at 72 °C, total volume of 20 μl). Formelting curve analysis, the tem-
perature was elevated slowly from 60 °C to 95 °C. Data were acquired
and analyzedwith theOpticonMonitor software (version 2). The ampli-
fication kinetics were recorded as sigmoid progress curves, for which
thefluorescencewas plotted against the number of amplification cycles.
The threshold cycle number (CT) was used to define the initial amounts
for each template. CT was the first cycle, for which a detectable fluores-
cence signal was observed. Homogeneity of the amplified PCR products
was tested bymelting-curve analysis. The initial template concentration
varied between 2 × 103 and 106 copy numbers and a reaction volume of
20 μl was adjusted.
To confirm the expression differences of our target genes on the pro-
tein level we carried out immunoblotting for ALOX15 and COX2. Unfor-
tunately, owing to the large concentrations of hemoglobin in the protein
extracts of the blood cells we were unable to detect specific immunore-
active bands in the expected molecular weight range. Our attempts to
specifically remove the hemoglobin from the protein extracts were
not successful and thus, these experiments were not very informative.
2.11. Serum biomarkers and anthropometrics
Prior to blood collection all patients were on an overnight fast and
samples were always taken at the same time (±1 h). Blood count, and
glucose were analyzed according to international standards at all visits.
Serum and plasmawere stored at−80 °C. For the quantitative determi-
nation of 3-hydroxybutyrate we used the cyclic enzymatic Wako
Autokit 3-HB and Insulin was measured with PerkinElmer AutoDELFIA
time-resolved fluoroimmunassay (B080-101). Body weight, fat and
lean masses were specified by Air-Displacement Plethysmography
(Bod Pod, Life Measurements, Inc. Concord, CA), BMI was calculated as
weight (kg)/height2(m).
2.12. Statistical analysis
To test uniformity of the variables baseline characteristics of the
three intervention groups (AKD, CR, CD) were first compared using
the non-parametric Kruskal-Wallis test. Owing to the small n-number
of the CR group (n = 5) reliable statistical analyses was not possible.
To overcome this problemwe combined the to two dietary intervention
groups (CR and AKD) to a joint ketogenic approach (KA) group. Two
sets of experimental data justified this data combination: i) The two in-
tervention groups (CR and AKD) showed similar results in the gene ex-
pression experiments: ii) Caloric restriction and the employed adapted
ketogenic diet induce similar metabolic alterations, which are indicated
by an increase in peripheral keto bodies. Combination of the gene ex-
pression data from the two dietary intervention groups did increase
the statistical power of our study. Under these conditions we observed
statistically significant differences between the pooled treatment
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tected when the two intervention groups were separately evaluated.
All differences between the control group and the ketogenic approach
(KA) group were calculated using analysis of covariance (ANCOVA) to
adjust for baseline dependencies. ANCOVAwas reported as themost re-
liable method in trials with baseline and follow up measurements [49].
For intra-group comparison (comparison of a corresponding variable
for an individual of an intervention group before and after dietary inter-
vention) before and after dietary intervention) we used the paired Stu-
dents t-test. Baseline associations between variables were assessed
using Spearman's rank correlation coefficient (rs). All tests should be
understood as constituting exploratory data analysis, as no previous
power calculation and adjustments for multiple testing were made. All
graphs are based on mean and standard error of the mean (SEM) data.
The test level for statistical significance of differences between (inter-
group comparisons) and within (intra-group comparison) the treat-
ment groups was defined as p = 0.05 (two-sided) for all tests. For sta-
tistical analyses the following software was used: SPSS, version 21
(IBM, Armonk, New York, US) and Graph Pad Prism, Version 5.04
(GraphPad Software, CA, US).
3. Results
3.1. Situation prior to dietary intervention
3.1.1. Baseline inter-group comparison: no differences in readout
parameters
Patients demographics did not differ significantly when the different
intervention groups were compared (Table 1). The Disease Modifying
Treatments (DTM) (Glatirameracetate and Interferone beta) were sig-
nificantly different between the groups but this is not relevant because
all participants were stable on their DMT at least six months prior to in-
clusion an did not change the DMT during the study. When we com-
pared the expression levels of the genes of interest (ALOX5, ALOX15,
COX1, COX2) we did not observe significant differences between the
three groups prior to dietary interventions (Table 1). These data indicate
that the different dietary habits of the patients involved in the study did
not significantly impact the expression patterns of the genes of interest.
Nevertheless, since even small differences in baseline expression levels
might impact the basic conclusions, we used baseline expression as co-
variate for all inter-group evaluations. In order to control our data for
plausibility we first analyzed (Table 2; Supplemental Fig. S1a–d;Table 1
Baseline differences between the three dietary groups. Data aremean (SD), number (%) ormedi
= caloric restriction diet, AKD = adapted ketogenic diet).
Baseline characteristics CD (n = 8) SD IQR C
Age in years 47.5 10.8 3
Gender F/M 6/2 (75/25) 4
Expanded disability status scale 2.8 1,5–4 2
Disease Duration in years 7.6 2.9 3
Relapse rate 12 months prior study outset 0.13 0.4 0
No immune modulating drugs 2 (25) 0
Glatirameracetate 5 (63) 1
Interferon Beta 0 4
Fingolimod 0 0
Natalizumab 1 (12.5) 0
BMI 27.6 8.4 2
Percent Body Fat 38.2 12.7 3
Fasting Blood Sugar mmol/l 4.5 0.6 4
Insulin mU/l 6.8 3.6 9
ß-Hydroxy-butyrat mmol/l 94.04 54.85 1
Neutrophils/nl 3.2 0.7 3
COX1b 19687 6577 1
ALOX5b 213708 65541 2
COX2b 13282 5978 1
ALOX15b 74814 59677 6
a non parametric Kruskal Wallis Test to compare between all three groups.
b Data are mean mRNA copies/106 GAPDH mRNA copies.Supplemental Table 2) the cross-group correlation (involving all indi-
viduals of all experimental groups at baseline) with respect to the fol-
lowing readout parameters:
3.1.2. The expanded disability status scale (EDSS) did inversely correlate
with Multiple Sclerosis Quality of Life-54 (MSQOL-54) index
Initially we compared the two clinically most relevant readout pa-
rameters (MSQOL-54 and EDSS) quantified in our study. The MSQOL-
54 score, which was determined by a questionnaire, mirrors the degree
of subjectivewellbeing of thepatients. The EDSS scorewas calculated on
the basis of the outcome of neurological examination and quantifies the
degree of neurological disability. We found a highly significant inverse
correlation (p = 0.00004, r = −0.734) between these two clinical
scores (Table 2 + Supplemental Fig. S1a) confirming that patients
reporting limitations in their quality of life suffer frommore severe neu-
rological dysfunctions [50].
3.1.3. Positive correlation between ALOX5 and COX2 gene expression
At baseline we observed a significant cross-group correlation (p =
0.001, r = 0.618) between the expression of COX2 and ALOX5 in pe-
ripheral leukocytes (Table 2 + Supplemental Fig. S1b). Both enzymes
catalyze key reactions in the biosynthesis of pro-inflammatory media-
tors (ALOX5 is the key enzyme of leukotriene formation and COX2 cat-
alyzes the initial reaction in the biosynthesis of pro-inflammatory
prostaglandins) and thus, a parallel upregulation of their expression is
biologically meaningful (see discussion).
3.1.4. Expression levels of ALOX5 and ALOX15 positively correlated with the
counts of different white blood cells
Next, we carried out cross-group correlation analysis for the expres-
sion levels of pro- and anti-inflammatory target genes (ALOX15, ALOX5,
COX1, COX2) and the counts of circulating blood cells (neutrophils, eo-
sinophils and basophils). Here, we observed a statistically significant
positive correlation between ALOX5 expression and the neutrophil
count (p=0.002, r=0.599, Table 2+ Supplemental Fig. S1c). This cor-
relation is not surprising since among peripheral blood cells neutrophils
are a rich source of ALOX5 expression. Furthermore, we detected a sig-
nificant positive correlation between ALOX15 expression and the
counts of eosinophils (p=5.3−9, r=0.891, Supplemental Fig. S1d), ba-
sophils (p= 0.012, r = 0,504, Supplemental Fig. S1e) and lymphocytes
(p=0.031, r=0.441 Supplemental Fig. S1f). The highly significant pos-
itive correlation of ALOX15 expression and the eosinophil count can bean (inter quartile range). Baseline datawere available for 24 patients (CD=control diet, CR
R (n = 5) SD IQR AKD (n = 11) SD IQR ap-value
6.2 12.8 43.1 8.8 0.3618
/1 (80/20) 10/1 (91/9) 0.6514
1.8–3.5 3.1 2.0–3.5 0.838
.5 3.1 6.1 4.5 0.1864
.4 0.5 0.27 0.5 0.5372
4 (36) 0.313
(20) 1 (9) 0.0413
(80) 3 (27) 0.0102
2 (18) 0.2907
1 (9) 0.7343
6.4 7.1 25.9 4.3 0.9824
2.1 12.8 35.6 9.8 0.5518
.5 0.4 4.3 0.6 0.779
.4 2.7 7.8 3.0 0.1013
67.1 155.7 123.2 78.03 0.7468
.9 2.5 3.7 1.6 0.8766
7269 6776 21134 8610 0.7108
28977 82679 279228 105975 0.4555
8312 7435 20219 5913 0.0569
3052 46475 52652 28327 0.8139
Table 2
Baseline analysis of cross-group (n = 24) correlation between the target gene expression and disease related or subject reported parameters.
Parameter ALOX5 ALOX15 COX1 COX2 EDSS
COX2 Neutrophils Physical Function Eosinophils Basophils Lympho-cytes Physical Health Physical Function EDSS Physical Function
aCorrelation Coefficient 0.618 0.599 −0.412 0.891 0.504 0.441 −0.563 −0.255 0.286 −0.734
p (2-tailed) .001 .002 .045 b.000001 .012 .031 .012 .229 .176 b.0001
EDSS = Expanded Disability Status Scale.
a Spearmans Rho.
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are the richest source of ALOX15 expression [51–53].
3.1.5. The quality of life indexMSQOL-54did inversely correlatewith the ex-
pression of pro-inflammatory genes
Finally, we correlated the MSQOL-54 index as clinically most rele-
vant parameter of patients' personal wellbeing with the expression
levels of key enzymes of eicosanoid biosynthesis in a cross-group ap-
proach. In theory, a high MSQOL-54 index, which indicates that the pa-
tients feel well, should inversely correlate with the expression levels of
classical pro-inflammatory enzymes. We found that ALOX5 expression
did inversely correlate with the MSQOL-54 index (p = 0.045, r =
−0.412). Similarly, we observed a significant inverse correlation (p =
0.012, r = −0.563) between COX1 expression and the MSQOL-54
index (Table 2 + Supplemental: Fig. S1g, h and Table S2). A trend for
an inverse correlation was also observed when COX2 expression was
correlated with the MSQOL-54 index but owing to the relatively small
n-numbers this correlation did not reach the level of statistical signifi-
cance (Supplemental: Table S2 + Fig. S1i).
The EDSS index was expected to positively correlate with the ex-
pression levels of pro-inflammatory enzymes as rising EDSS scores re-
flect increasing neurological dysfunction. We observed for all target
genes a statistical trend for positive correlation with the EDSS index
but owing to the relatively small n-numbers these correlations did not
reach the level of significance (Supplemental: Table S2 + Fig. S1j
+ k). The scattered plots visualizing the correlation of the different
readout parameters are given in supplemental Fig. S1.
3.2. Expression alterations of target genes as consequence of dietary
intervention
3.2.1. Intra-group comparison: ketogenic diets induced significant reduc-
tions in the expression of pro-inflammatory genes in peripheral blood
leukocytes
The data summarized in the supplemental Fig. S2a–d and in the sup-
plemental Table S3 suggest that treatment of the patients with the two
different types of ketogenic diets (CR and AKD) down-regulated the ex-
pression levels of all target enzymes. In fact, after dietary intervention
the gene expression rates are always smaller than in patientswith nodi-
etary intervention. In contrast, in the control group the gene expression
rates before study onset and during the study are always similar. To im-
prove the statistical power of our studywe pooled the CR+AKDgroups
to one “ketogenic approach” (KA) group. For intra-group comparison
we quantified the readout parameters of all individuals in the treatment
group before and after dietary intervention. Similarly, we quantified the
corresponding readout parameters of the individuals in the control
group. The members of the control group did not receive a special diet
and thus, there should not be any differences in the gene expression
levels before and after the intervention period (Fig. 1a–d). As expected
there was no significant difference in the expression level of any gene
product in the control group. Thisfinding excludes unspecific dietary ef-
fects on the expression of the target genes. When we profiled the ex-
pression of Cyclooxygenase-1 (Fig. 1a) within the pooled ketogenic
approach group (KA) we found a significant decrease in the expression
levels from19,927COX1mRNAcopies per 106 GAPDHcopies at baseline(no dietary intervention) to 11,824 COX1 mRNA copies per 106 GAPDH
copies (p b 0.001; 95% CI -12,179 to−4026) after intervention. A similar
decline was also observed for expression of pro-inflammatory 5-
Lipoxygenase from 263,524 ALOX5mRNA copies per 106 GAPDH copies
at baseline to 145,441 ALOX5 mRNA copies per 106 GAPDH copies (p b
0.0005; 95% CI -172,249 to −63,918) after the treatment period
(Fig. 1b). Moreover, we observed a significant drop in the expression
level of pro-inflammatory Cyclooxygenase-2 (Fig. 1c) from 19,623
COX2 mRNA copies per 106 GAPDH copies at baseline to 12,484 COX2
mRNA copies per 106 GAPDH copies (p b 0.05; 95% CI 12,643 to 1634)
on diet. In contrast, expression of 15-Lipoxygenase in peripheral
leucocytes was not significantly altered by dietary intervention
(Fig. 1d).
3.2.2. Inter-group comparison: ketogenic diets lower ALOX5 expression in
comparison to normal diet
Next, we compared the expression levels of the target genes be-
tween the members of the control group and the pooled dietary inter-
vention groups (KA). In this inter-group comparison we found that
the difference in COX2 expression between the members of the control
group and the members of the pooled dietary intervention groups did
not reach the level of statistic significance (Table 3 + Supplemental
Fig. S3a). Similar observations were made for ALOX15 (Table 3 + Sup-
plemental Fig. S3b). However, we observed (Fig. 2 + Table 3) a signifi-
cant decrease in the gene expression levels of ALOX5 when the
members of the control group were compared with the members of
the pooled KA group (adjusted difference 89,010 ± 42,201; 95% CI
1249 to 176,772 ALOX5 mRNA copies/106 GAPDH mRNA copies, p b
0.05). In this inter-group comparison we also observed a statistic
trend for declined expression of COX1 (adjusted difference 5890 ±
3238; 95% CI 843 to 12,623 COX1mRNA copies/106 GAPDHmRNA cop-
ies) but the p-value of 0.08 suggested only borderline significance
(Table 3 + Supplemental Fig. S3c).
3.3. Changes in body composition and blood parameters change as conse-
quence of ketogenic intervention
3.3.1. Inter-group comparison indicates no differences in baseline readout
parameters
First, we compared BMI, fasting blood sugar, ketone bodies (ß-hy-
droxy-butyrate), insulin and neutrophil counts between the three ex-
perimental groups before the intervention. Here we did not observe
any significant differences (Table 1 + Supplemental Fig. S4a–e).
3.3.2. Ketogenic approaches reduce BMI and increase ketone body levels in
comparison to normal diet
Caloric restriction and an adapted ketogenic diet are known to in-
duce weight loss, to increase the levels of ketone bodies in the blood,
and to reduce the circulating insulin and glucose concentrations.
These metabolic alterations are characteristic for a diet defective in car-
bohydrates. We compared BMI, blood glucose, ß-hydroxy-butyrate, in-
sulin and neutrophil levels between control individuals and those
patients receiving a ketogenic diet (KA) (Table 4 + Supplemental
Fig. S4). Here we observed significantly elevated beta hydroxybutyrate
blood levels (adjusted difference 1442.3 mmol/l ± 537.7; 95% CI for
Fig. 1. Intra-group comparison - Ketogenic approaches lower the gene expression of pro-inflammatory enzymes involved in eicosanoid biosynthesis. (a–d) Alterations of gene expression
induced by caloric restriction/adapted ketogenic diet (ketogenic approaches)when comparedwith commonwestern diet (control diet). The steady state concentrations (copy numbers of
target genemRNA per 106 copies of GAPDHmRNA) for the following transcripts were evaluated: a) COX1, b) ALOX5, c)COX2, and d) LOX15. Data representmean± standard error of the
mean (SEM) and were measured at baseline and retested between day 8 and 17 after the onset of dietary intervention. Horizontal bars indicate paired t-Test analysis.
Table 3
Impact of ketogenic approaches (KA) on expression of pro−/anti-inflammatory enzymes
when compared with common western diet (CD). Adjusted comparison between pooled
ketogenic approaches (caloric restriction + adapted ketogenic diet) and control group
(commonwestern diet). Data were available for 24 patients (CD= control diet, KA= ke-
togenic approaches) and were measured at baseline and retested between day 8 and 17
after the onset of dietary intervention.MeanmRNA copies/106 GAPDHmRNA copies (SD).
Gene Timepoint CD (n = 8) SD KA (n = 16) SD ap-value
COX1 Baseline 19687 6577 19927 8068
Treatment 17564 8748 11824 8717 0.083
ALOX5 Baseline 213708 65541 263524 99442
Treatment 226943 101181 145441 88723 0.047
COX2 Baseline 13282 5978 19623 6235
Treatment 13953 8060 12484 9181 0.842
ALOX15 Baseline 74814 59677 55902 33700
Treatment 74392 58376 40614 31658 0.143
a Analysis of covariance (ANCOVA) to adjust for baseline dependencies.
M. Bock et al. / EBioMedicine 36 (2018) 293–303difference 324.1 to 2560.4, p b 0.05) and a significant loss in BMI (ad-
justed difference−0.78 ± 0.3; 95% CI for difference−1.3 to−0.2, p b
0.01).
3.3.3. Distinct effects of CR and AKD on BMI, insulin and ketone body levels
Under our experimental conditions CR was more efficient in reduc-
ing BMI, inducing ketosis and lowering insulin levels when compared
with AKD (Supplemental Table 4). In fact, an inter-group comparison
of the two types of ketogenic diets revealed three interesting results:
i) CR induced a significantly stronger reduction in BMI (adjusted differ-
ence−1.248± .184; 95% CI for difference−1.632 to−.865, p b 0.001).
ii) CR induced significantly higher beta hydroxybutyrate concentration
(adjusted difference 2131.1 mmol/l ± 486.6; 95% CI for difference
1116 to 3146.3, p b 0.001). iii) CR induced significantly lower blood in-
sulin levels (adjusted difference−3.602mU/l± 1.222; 95% CI for differ-
ence−6.201 to−1.103, p b 0.01).
Fig. 2.Ketogenic approaches (KA) lower ALOX5 expression in the inter-group comparison
to common western diet (CD). Comparison of ALOX5 gene expression during caloric
restriction and adapted ketogenic diet (pooled ketogenic approach group, n = 16) with
common western diet (control diet). Data were measured at baseline and retested
between day 8 and 17 after the onset of dietary intervention. See also supplemental
Fig. S2a–c for COX1, COX2, and ALOX15 expression results. Data represent mean ±
standard error of the mean (SEM). *p ≤ 0.05, analysis of covariance (ANCOVA) to adjust
for baseline dependencies.
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This study is – to the best of our knowledge – the first study that in-
vestigated the impact of ketogenic diets (CR and AKD) on the gene ex-
pression profiles of key enzymes involved in eicosanoid biosynthesis
(ALOX5, ALOX15, COX1 and COX2) in multiple sclerosis patients.
Employing a strictly quantitative real-time PCR approach we were
able to explore whether expression of selected target genes were up-
or downregulated in peripheral blood leukocytes during dietary inter-
vention in MS patients. One such gene with obvious implications for
MS pathology is ALOX5, the expression of which was significantly
downregulated in peripheral blood leukocytes during dietary interven-
tion. The expression product of the ALOX5 gene (5-lipoxygenase) cata-
lyzes the two initial steps in the conversion of arachidonic acid to
biologically active leukotrienes. As classical pro-inflammatory media-
tors leukotrienes induce an increase in the vascular permeability during
inflammation, trigger leukocyte migration and improve leukocyte che-
motaxis. Moreover, leukotrienes induce tissue edema, play an impor-
tant role in host defense mechanisms against pathogens and promote
disruption of the blood brain barrier [27,54–58].
However, the precise role of ALOX5 in the pathogenesis of MS is far
from clear. In fact, controversial data have been obtained in mouse ex-
perimental MS models (Emerson and LeVine, [13]) and in MS patients
(Mirshafiey and Jadidi-Niaragh, [18]). But even in the mouse EAETable 4
Impact of ketogenic approaches (KA)onanthropometric,metabolic and immunologic out-
come when compared with common western diet (CD). Adjusted comparison between
pooled ketogenic approaches (caloric restriction + adapted ketogenic diet) and control
group (common western diet). Data were available for 24 patients (CD = control diet,
KA = ketogenic approaches).







BMI Baseline 27.61 8.4 26.05 5.1
Treatment 27.62 8.3 25.31 5.0 0.008
Fasting Blood Sugar
mmol/l
Baseline 4.52 0.6 4.40 0.5
Treatment 4.52 0.5 3.99 1.1 0.241
Insulin mU/l Baseline 5.75 3.6 8.288 2.9
Treatment 5.75 2.4 5.481 2.8 0.493
ß-Hydroxy-butyrat
mmol/l
Baseline 94.04 54.9 136.9 104.7
Treatment 92.53 106.8 1439.2 1451.3 0.014
Neutrophils/nl Baseline 3.241 0.7 3.763 1.9
Treatment 3.459 0.9 2.952 1.1 0.176
a Analysis of covariance (ANCOVA) to adjust for baseline dependencies.model controversial roles of ALOX5 have been reported. Inactivation
of the ALOX5 gene leads to exacerbation of the neurological symptoms
(Emerson and LeVine, [13]) suggesting a protective role of ALOX5 in this
animal disease model. On the other hand, pharmacological inhibition of
the ALOX5 pathway delayed the onset of EAE and reduced disease se-
verity (Marusic et al., [14]). These data suggest a promoting role of
ALOX5 in EAE pathogenesis. This conclusionwas supported bymore re-
cent finding that leukotriene B4 (LTB4), the biosynthesis of which re-
quires a functional ALOX5, promotes Th17 lymphocyte differentiation
and improves recruitment of these cells into the brain of EAE mice
[59,60]. According to these data ALOX5 contributes to neuroinflamma-
tion in the EAE model. In summary, it may be concluded that the role
of ALOX5 in the pathogenesis of MS is still a matter of discussion and
that additional experimental data are needed to characterize the precise
role of this enzyme in inflammatory cerebral diseases.
Cyclooxygenase-isoforms (COX1, COX2) are key enzymes in the bio-
synthesis of pro-inflammatory prostaglandins since these two enzymes
catalyze the rate-limiting step in the formation of these lipid mediators
[61–63]. COX1 is constitutively expressed in many cells and tissues
whereas expression of COX2 is strongly upregulated in activated inflam-
matory cells [64]. In neurons, COX2 expression is induced by glutamate
receptor agonists and inhibition of COX2 exhibits beneficial effects in
themouse EAEmodel [14,23,65–69]. In humans another group reported
that Th17 cells fromMS patients expressed higher levels of prostaglan-
din EP2 receptors and that overexpression of EP2 in Th17 cells from
healthy adults induced a pathogenic Th17 gene expression profile
[70]. Thus the development of pathogenic autoreactive Th17 cells
seems to be directly linked to PGE2 signaling. Interestingly PGE2 exerts
anti-inflammatory properties by EP4 receptor-mediated action [71].
Moreover, a Th17/Treg imbalance is characteristic of childhood intracta-
ble epilepsy and was corrected by ketogenic diet [72].
Inhibitors of COX-isoforms are frequently prescribed as non-
steroidal anti-inflammatory drugs (NSAIDs) but they may also exhibit
neuroprotective activity [66,67,73,74]. Because of their pharmacological
profile NSAIDs have been employed for themanagement of side effects,
when interferon beta is employed for multiple sclerosis treatment.
Moreover, the classical COX1 inhibitor aspirin is frequently used to
limit the severity of multiple sclerosis related fatigue and premenstrual
associated pseudo-exacerbations [75–77]. Although COX1 in contrast to
COX2 may not be considered a classical pro-inflammatory enzyme it
contributes to the biosynthesis of pro-inflammatory prostaglandins
[63]. Consequently, patients with high ALOX5 and COX1 expression
levels are likely to develop more severe inflammatory symptoms.
The use of COX-2 inhibitors for treating multiple sclerosis has cur-
rently been challenged owing to cardiovascular side effects of some
COX-2 inhibitors [78,79]. Our intra-group comparisons indicated that
expression of COX1 and COX2 in human peripheral leukocytes is down-
regulated by ketogenic diets and these data may explain the beneficial
effects of these types of diet for multiple sclerosis patients. Moreover,
our data are consistentwith previous findings of other groups reporting
that AKD impaired systemic and local COX2 gene expression [80–82].
Interestingly, we found an association of COX- and LOX-isoforms ex-
pression with the MSQOL-54 index, which did robustly correlate with
the neurological symptoms (EDSS index), which does notmean a causal
connection between expression levels of our target genes and disease
symptoms [50]. Furthermore, previous cross-sectional and longitudinal
studies have indicated that the MSQOL-54 index did correlate with le-
sion burden and brain volume measures even in early stages of MS
[83,84]. Althoughwe did not directlymeasure suchmorphological read-
out parameters it might well be that the expression of COX/ALOX-
isoforms in peripheral leukocytes may have predictive value for the ex-
tent of such morphological alterations. However, to definitely answer
this question a more powerful case-control study must be carried out,
in which these morphological characteristics are directly determined.
We recently reported that ketogenic diets in MS patients improved
the MSQOL-54 index and lowered the peripheral lymphocyte count
M. Bock et al. / EBioMedicine 36 (2018) 293–303[45]. These data suggest that this therapeutic approach may silence the
intensity of the immune response,whichmight slowdown the progress
of the disease. Although our intra-group comparisons suggest that ex-
pression of the classical pro-inflammatory enzymes COX2 and ALOX5
in peripheral leukocytes is silenced by ketogenic diets these data have
to be interpreted with caution. In fact, our inter-group comparisons
did not confirm these data for COX2 and thus, additional studies are re-
quired to prove or disprove this hypothesis. On the other hand, our ob-
servations are consistent with the outcome of previous studies [80–82],
which indicate that ketogenic diet reduces the activity of pro-
inflammatory enzymes. Dual inhibition of the COX/LOX pathways in
neuroinflammatory diseases induced promising alterations [85–87]
but the future will tell whether these promises can be confirmed in
large clinical trials. The mechanisms on how ketogenic diets reduce
COX/LOX gene expression remain still elusive but it is likely that during
the initial mitochondrial and cellular adaptation to ketogenic diets ROS
is involved in the regulation of gene expression of several target en-
zymes [80,88]. Thus a complex interaction of ROS as effector molecules
to orchestrate gene networksmay regulatemajor intracellular signaling
cascades and cellular homeostatic mechanisms under ketogenic diets
[80].
Our data have indicated a significant correlation between the ex-
pression level of ALOX5 and the blood counts of eosinophils, basophils,
neutrophils and lymphocytes. These data are not surprising since all leu-
kocytic cell types are rich sources for this classical pro-inflammatory en-
zymes [58,61,62,89]. The ketogenic diets did not suppress circulating
neutrophils (Table 4 Supplemental Table S4), which could have been
also an explanation of an ALOX5 decrease.
The steady state concentration of ALOX5mRNA in peripheral leuko-
cytes is higher than COX1 and COX2mRNA levels. This is an interesting
finding but it remains to be exploredwhether a similar ratio can be con-
firmed on the protein level. To address this question we performed im-
munoblot experiments for ALOX15 and COX2 but were not able to
obtain specific signals in the expected molecular weight range. In
these experiments we struggled with the large hemoglobin concentra-
tions in the blood cell samples, which interfered with immunostaining.
Our attempts to specifically remove the hemoglobin form the samples
were not successful and thus, for the time being it remains unclear
whether the mRNA levels quantified in this study mirror the in vivo ac-
tivities of the corresponding enzymes. To answer this question quanti-
tative metabolome studies should be carried out in the future.
We also observed that expression of ALOX5 and COX2 in peripheral
leukocytes did correlatewith each other. Although themolecularmech-
anisms of gene expression regulation of the two enzymes are very dif-
ferent both enzymes constitute classical pro-inflammatory gene
products and thus, parallel expression regulation is biologically mean-
ingful [58,61,62,89]. However, it remains unclear which molecular
mechanisms are the basis for parallel expression regulation of these
two enzymes. A compensatory shunting of arachidonic acidmetabolism
between the two pathways is possible and has been reported for other
conditions [90–92]. We also noticed that the HOMA-IR (unpublished
data) improved under both ketogenic treatments, which is clinically
meaningful because insulin resistance seems to be associated with dis-
ability, chronic inflammatory processes and oxidative stress [93–95].
A major limitation of our study is its small sample size (n= 24 ana-
lyzed patients vs. n= 48 total patients who finished the study) and the
limited selection of target genes. However, based on our results more
comprehensive expression profiles (genome covering expression mi-
croarrays), which also quantify the expression other classical pro- and
anti-inflammatory gene products, should be carried out during follow-
up studies. Thus, there is urgent need for follow up and validation of
our results with a larger cohort. However, despite this caveat our
study suggests that ketogenic diets offer an elegant way to modulate
leukocytic ALOX/COX expression, which seems to be a promising effect
in neuro-inflammatory diseases [87,96]. Our findings are of immediate
medical interest since such dietary therapeutic strategies have wellbeen characterized in the past decades and exhibit little unwanted
side effects [44,45,97].
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